Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Viewpoint

Vol. 150 No. 3334 (2020)

The role of clinical inertia in suboptimal management of gout

  • Leonardo Punzi
DOI
https://doi.org/10.4414/smw.2020.20334
Cite this as:
Swiss Med Wkly. 2020;150:w20334
Published
19.08.2020

References

  1. Meier R, di Gangi S, Valeri F, Rosemann T, Zechmann S, and the FIRE study group. Gout management in Swiss primary care - a retrospective observational study. Swiss Med Wkly. 2020;150:w20209. doi:.https://doi.org/10.4414/smw.2020.20209
  2. Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, et al. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis. 2008;67(7):960–6. doi:.https://doi.org/10.1136/ard.2007.076232
  3. Singh JA, Gaffo A. Gout epidemiology and comorbidities. Semin Arthritis Rheum. 2020;50(3S):S11–6. doi:.https://doi.org/10.1016/j.semarthrit.2020.04.008
  4. Richette P, Bardin T. Gout. Lancet. 2010;375(9711):318–28. doi:.https://doi.org/10.1016/S0140-6736(09)60883-7
  5. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Ann Rheum Dis. 2015;74(4):661–7. doi:.https://doi.org/10.1136/annrheumdis-2013-204463
  6. Punzi L, Scanu A, Spinella P, Galozzi P, Oliviero F. One year in review 2018: gout. Clin Exp Rheumatol. 2019;37(1):1–11.
  7. Phillips LS, Branch WT, Jr, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825–34. doi:.https://doi.org/10.7326/0003-4819-135-9-200111060-00012
  8. Maravic M, Hincapie N, Pilet S, Flipo R-M, Lioté F. Persistent clinical inertia in gout in 2014: An observational French longitudinal patient database study. Joint Bone Spine. 2018;85(3):311–5. doi:.https://doi.org/10.1016/j.jbspin.2017.03.013
  9. Punzi L, Medea G. Understanding and perceptions of gout: an interdisciplinary assessment among patients, physicians and pharmacists in Italy. Reumatismo. 2020;72(1):31–43. doi:.https://doi.org/10.4081/reumatismo.2020.1227
  10. Bardin T. Hyperuricemia starts at 360 micromoles (6 mg/dL). Joint Bone Spine. 2015;82(3):141–3. doi:.https://doi.org/10.1016/j.jbspin.2015.01.002
  11. Desideri G, Castaldo G, Lombardi A, Mussap M, Testa A, Pontremoli R, et al. Is it time to revise the normal range of serum uric acid levels? Eur Rev Med Pharmacol Sci. 2014;18(9):1295–306.
  12. Pascart T, Latourte A, Flipo R-M, Chalès G, Coblentz-Baumann L, Cohen-Solal A, et al. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy. Joint Bone Spine. 2020. [Online ahead of print]. doi:.https://doi.org/10.1016/j.jbspin.2020.05.002
  13. Abhishek A, Jenkins W, La-Crette J, Fernandes G, Doherty M. Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care-5-year follow-up of a proof-of-concept study. Rheumatology (Oxford). 2017;56(4):529–33. doi:.https://doi.org/10.1093/rheumatology/kew395

Most read articles by the same author(s)